News Market Reports CEO Interview Series Events & Exhibitions

Benitec Limited

ASX:BLT ISIN:AU000000BLT8

Feb 10, 2012

OVERVIEW | NEWS | MULTIMEDIA | RESEARCH

Benitec Limited Company Summary

Benitec Limited (ASX:BLT) (PINK:BNIKF) holds a dominant position in expressed RNA interference (RNAi)-based human therapeutics, with a transformational platform technology supported by a robust and extensive intellectual property portfolio. Benitec is leveraging this platform to develop and build a pipeline of expressed RNAi therapeutics focusing on treatment and alleviation of cancer and infectious disease. With strong global partnerships and committed scientific and clinical investigators, Benitec Ltd aims to deliver a range of novel RNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry.

DIRECTORS / OFFICERS

Peter Francis LLB Grad Dip (Intellectual Property) Non-executive Chairman Mr Peter Francis is a partner at Francis Abourizk Lightowlers (FAL), a firm of commercial and technology lawyers with offices in Melbourne, Australia. He is a legal specialist in the areas of intellectual property and licensing and provides legal advice to a large number of corporations and research bodies.
Mel Bridges BAppSc FAICD Executive Director Mr Mel Bridges has more than 30 years experience in the global biotechnology and healthcare industry. During this period, he founded and managed successful diagnostics, biotechnology and medical device businesses. Mel is currently Chairman of a number of listed and unlisted companies. He is Chairman of Alchemia Ltd and Impedimed Limited. He also co-founded the listed company Panbio Ltd. Mel has extensive experience as a public company director and has been recently appointed to the board of Campbell Brothers Limited. Mel is also an Non-Executive Director of Tissue Therapies Limited and Genera Biosystems Limited.
John Chiplin Ph.D Executive director Dr John Chiplin has broad-based experience in the life science and technology industries, both from an operational and investment perspective. His most recent accomplishment was the corporate reengineering of Arana Therapeutics, a world leading Antibody developer, which resulted in the acquisition of the company by Cephalon for a significant premium to market (July 2009). Immediately prior to running Arana, Dr. Chiplin was head of the $300M ITI Life Sciences investment fund in the UK. His own investment vehicle, Newstar Ventures Ltd, has funded more than a dozen early stage companies in the past ten years. Dr. Chiplin’s Pharmacy and Doctoral degrees are from the University of Nottingham, UK. In addition to Benitec, John currently serves on the Boards of Progen Pharmaceuticals Limited and ScienceMedia, Inc.

ANNUAL REPORT

PRESENTATIONS

COMPANY DATA

	Headquarters	Level 16, 356 Collins Street

		Melbourne Vic 3000

		Australia

	Telephone	+61-3-8456-6281

	Fax	+61-3-8678-1342

	Principal Sector	Health & Pharm

	Principal Industry	Biotechnology

	Listed	17/02/1997

	Homepage	www.benitec.com

Key Developments: Benitec Limited

	Benitec Limited (ASX:BLT) Announce Capital Raising And Changes To Capital Funding Arrangements APR 11, 2011 08:52 - Article Views: 1,452 Benitec Limited (ASX:BLT) (PINK:BNIKF) is pleased to announce that it is undertaking a fully underwritten Renounceable Rights Issue to raise approximately $8 million, following an agreement reached with La Jolla Cove Investors Inc to terminate their convertible note funding arrangement with Benitec.

	Benitec Limited (ASX:BLT) Technology Used By University Of Queensland Scientists To Develop A Treatment For Cervical Cancer MAR 29, 2011 14:24 - Article Views: 1,453 Benitec Limited (ASX:BLT) (PINK:BNIKF) today welcomed the publication of research by scientists at the University of Queensland who demonstrated the value of Benitec's gene silencing platform technology to provide effective human therapeutics for cancer. Their results were published this month in the prestigious international scientific journal Cancer Gene Therapy.

	Benitec Limited (ASX:BLT) RNAi Patent Update MAR 22, 2011 13:56 - Article Views: 1,364 Benitec Limited (ASX:BLT) (PINK:BNIKF), a world leader in expressed gene silencing for human therapeutics, today announced further positive progress in its fundamental Graham family patent applications exclusively licensed from CSIRO worldwide for human therapeutics. These patents cover silencing of genes using DNA-directed RNA interference (ddRNAi). Progress on these patent applications further strengthens Benitec's position with regards to both its revenue opportunities from licensing of ddRNAi technology for research use and in the commercialization potential of its ddRNAi-based therapeutics, being developed both in house and for the treatment of chronic and life threatening medical conditions, such as infectious diseases and cancer.

	Second US Clinical Study In HIV/AIDS Lymphoma Patients Using Benitec Limited (ASX:BLT) ddRNAi Technology MAR 21, 2011 10:59 - Article Views: 2,097 Benitec Limited (ASX:BLT) (PINK:BNIKF), a world leader in RNA-based gene silencing for human therapeutics, is pleased to acknowledge that the City of Hope research hospital in Duarte, California is planning to initiate a second small Phase I/II study using Benitec's DNA-directed RNA interference (ddRNAi) technology in lymphoma patients carrying the HIV virus. The aim of the study is to optimize the treatment by modifying a range of clinical parameters.

	Benitec Limited (ASX:BLT) Hepatitis B RNAi Program With Biomics Biotechnologies Moves To The Next Stage Following Successful Stage 1 Results FEB 22, 2011 12:33 - Article Views: 2,431 Benitec Limited (ASX:BLT) (PINK:BNIKF) announce that following the success of the first stage of its anti-viral program to develop an RNA interference (RNAi)-based therapy against Hepatitis B virus, conducted in collaboration with China-based Biomics Biotechnologies Co. Ltd, the companies have reached agreement to proceed to the next stage which is designed to develop an RNAi therapeutic to the point of pre-clinical studies in vivo.

	Benitec Limited (ASX:BLT) Announce Formation Of Chief Investigators Group FEB 18, 2011 12:02 - Article Views: 1,398 Benitec Limited (ASX:BLT) (PINK:BNIKF), a world leader in expressed gene silencing for human therapeutics, today announces the formation of the Benitec Chief Investigators' Group, bringing together the Company's scientific founders with its collaborative partners.

	Benitec Limited (ASX:BLT) Patent Update: Strengthening And Expansion Of Dominant Patent Position In RNA Interference FEB 17, 2011 12:31 - Article Views: 1,062 Benitec Limited (ASX:BLT) (PINK:BNIKF) announce that the United States Patent and Trademark Office has today indicated that it is issuing the Re-examination Certificate, the formal final step in the USPTO's confirmation of patentability of claims in the key '099 Graham Patent [US Patent No. 6,573,099] "Genetic Constructs for Delaying or Repressing the Expression of a Target Gene", the wide-ranging platform technology patent covering the use of expressed RNA Interference in human therapeutic applications.

	Benitec Limited (ASX:BLT) Receives Dividend from Licensee DEC 23, 2010 16:18 - Article Views: 1,594 Benitec Limited (ASX:BLT) (PINK:BNIKF) is pleased to advise that it will receive a dividend of US$161,674 from its licensee, the California-based biotechnology company, Tacere Therapeutics, Inc.

	Benitec Limited (ASX:BLT) Review Pending US Divisional Patent Applications DEC 16, 2010 15:42 - Article Views: 1,213 Benitec Limited (ASX:BLT) (PINK:BNIKF) announced today that, following the clarification provided by the re-examination decision for the landmark United States Patent 6,573,099 in RNA interference, it has reviewed the claim scope of the pending US applications with its US attorney and has determined a strategy for the continued prosecution of these applications to maximise their benefits, as presaged in the announcement regarding the R&D Pipeline and Strategy on 3 September 2010.

	Benitec Limited (ASX:BLT) Granted Another RNA Interference Patent In Europe Providing Further Support For The Hepatitis C Program DEC 13, 2010 11:38 - Article Views: 1,547 Benitec Limited (ASX:BLT) (PINK:BNIKF) is pleased to announce that the European Patent Office has issued a Communication of Intent to Grant on application 2005 727 680 "Multiple promoter expression cassettes for simultaneous delivery of RNAi agents".